Extended Data Fig. 7: Clinical characteristics of stage II/III patients in the TCGA-SKCM study. | Nature Medicine

Extended Data Fig. 7: Clinical characteristics of stage II/III patients in the TCGA-SKCM study.

From: Common germline variants of the human APOE gene modulate melanoma progression and survival

Extended Data Fig. 7

a, Sex proportions were not significantly different between APOE carrier groups (P = 0.46, χ2 test). b, Age at diagnosis was not significantly different between APOE carrier groups (P = 0.45, Kruskal-Wallis rank sum test). c, Tumor stage at diagnosis was not significantly different between APOE carrier groups (P = 0.4, χ2 test). d, Melanoma Clark level at diagnosis was not significantly different between APOE carrier groups (P = 0.95, χ2 test). e, Breslow depth was not significantly different between APOE carrier groups at diagnosis (P = 0.24, Kruskal-Wallis rank sum test). f, APOE carrier status was not significantly associated with common tumor mutations (P = 0.93, χ2 test). g, APOE carrier status was not significantly associated with transcriptomic cluster (P = 0.55, χ2 test). h, Univariate analysis of the impact of clinical and molecular characteristics on survival of stage II/III melanoma patients (P values according to univariate Cox proportional hazards model). i, Multivariable analysis of the impact of clinical and molecular characteristics with significant impact in univariate analysis on survival of stage II/III melanoma patients (P values according to multivariable Cox proportional hazards model). For (h-i), the number of patients with available information for a given characteristic is indicated in column “n”, and plots represent hazard ratios with 95% confidence intervals. Hinges of boxplots represent the first and third quartiles, whiskers extend to the smallest and largest value within 1.5 × interquartile ranges of the hinges, and points represent outliers.

Back to article page